-
Brand Name: ENDOPROST
-
Generic Name: Medroxyprogesterone Acetate (MPA)
-
Therapeutic Class: Synthetic Progestin
-
Form:
-
150 mg/mL (1 mL vial/prefilled syringe) – Depot form (IM only)
-
104 mg/0.65 mL (Subcutaneous option in some markets)
-
-
Duration: 3-month contraceptive protection per dose
2. Composition
-
Active Ingredient: Medroxyprogesterone Acetate (MPA)
-
Vehicle:
-
Polyethylene glycol (for IM suspension)
-
Preservative-free in some formulations
-
-
Excipients: Polysorbate 80, sodium chloride
3. Mechanism of Action
✔ Suppresses ovulation (inhibits LH surge)
✔ Thickens cervical mucus (blocks sperm entry)
✔ Atrophies endometrium (prevents implantation)
✔ Reduces FSH secretion → decreases ovarian follicular activity
4. Dosage & Administration
For Contraception
Dose | Route | Frequency |
---|---|---|
150 mg | Deep IM (gluteal/deltoid) | Every 12-14 weeks |
104 mg | Subcutaneous (upper arm/abdomen) | Every 12-14 weeks |
For Endometriosis/Hormonal Disorders
-
50-100 mg IM weekly (short-term use)
Key Notes:
-
Shake well before injection (suspension settles)
-
Do NOT give IV (risk of embolism)
-
Rotate injection sites
5. Indications
✅ Contraception (long-acting reversible)
✅ Endometriosis-associated pain
✅ Abnormal uterine bleeding (hormonal control)
✅ Palliative treatment of endometrial/breast cancer
6. Storage & Stability
-
Unopened: 20-25°C (avoid freezing)
-
After opening: Use immediately (discard unused portions)
-
Protect from light
7. Key Recommendations
✔ Baseline screening:
-
Pregnancy test (if uncertain)
-
BP measurement (may increase hypertension risk)
-
Bone density scan (if long-term use >2 years)
✔ Return to fertility:
-
Delayed by 6-12 months post-discontinuation
-
Advise alternative contraception if immediate pregnancy desired
✔ Missed dose:
-
If >14 weeks since last dose, rule out pregnancy before next injection
8. Important Safety Notes
⚠ Black Box Warnings:
-
Bone mineral density (BMD) loss (higher risk with >2 years of use)
-
Irreversible effects if used during puberty (under 18 years)
⚠ Contraindications:
❌ Active thromboembolic disorders
❌ Breast/reproductive organ cancers
❌ Unexplained vaginal bleeding
❌ Severe hepatic disease
⚠ Adverse Effects:
-
Common: Weight gain, amenorrhea, headaches
-
Serious:
-
Osteoporosis (long-term use)
-
Mood changes/depression
-
Increased diabetes risk
-
9. Comparison with Other Progestins
Feature | ENDOPROST (MPA) | Levonorgestrel IUD | Etonogestrel Implant |
---|---|---|---|
Duration | 3 months | 5 years | 3 years |
Bone Loss Risk | High | Minimal | Minimal |
Return to Fertility | Delayed (6-12 mo) | Immediate | Immediate |
Cost | $ | $$$ | $$ |
10. Patient Counseling
✔ Expect irregular bleeding (common in first 6 months) → usually resolves
✔ Weight management (3-5 kg gain typical)
✔ Calcium/Vitamin D supplementation (for bone health)
✔ Report:
-
Severe mood changes
-
Persistent leg pain (DVT risk)
-
Vision changes (rare intracranial hypertension)
Conclusion
ENDOPROST is a cost-effective, long-acting contraceptive but requires bone health monitoring with prolonged use. Ideal for patients needing non-daily, discreet birth control.
Reviews
There are no reviews yet.